XORTX Therapeutics

XRTX

Biotechnology · Healthcare

Price

$2.04

+0.02 (+0.99%)

Market Cap

$568,118

Exchange

NASDAQ Capital Market

Winston Score

–

No score yet — Winston is napping.

We couldn’t gather enough financial data to score this stock reliably.

Track this stock — start free trial

Share count rising — dilution

+332.7% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 44K (2021) → 189K (2025)

Winston Score History

The full picture

XORTX Therapeutics is a small Canadian biotechnology company focused on developing drugs to treat kidney disease. Its lead programs target conditions like autosomal dominant polycystic kidney disease (ADPKD) and acute kidney injury, which are serious conditions where the kidneys stop working properly. The company is in the clinical-stage, meaning its drugs are still being tested in humans and none have been approved for sale yet.

XORTX does not currently generate meaningful revenue, which is typical for early-stage biotech companies. It funds its research through equity financing, meaning it raises money by selling shares to investors. The company operates primarily in Canada and conducts clinical trials in partnership with research institutions. Its main risk is that it has no approved products, a very small cash base, and must continue raising money to survive — if its drug trials fail or funding runs dry, the company faces serious financial pressure.

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

Revenue data limited

EPS Growth

+78.5% YoY

YoY Growth Rate

EPS growth accelerating

R&D Spend

$574,935/ year

↑ Rising (+229% vs prior year)

R&D investment increasing — building for the future

Insider Activity

10.2%ownership

Insiders own a meaningful stake in the company

Cash Runway

~1 months

$2M cash & investments

Quarterly Free Cash Flow

↓ Burn rate worsening

Short runway — potential dilution ahead through share issuance

Cash watch

XORTX Therapeutics has less than a year of cash at its current burn rate. Growth investors should watch for potential share dilution from future fundraising — that directly reduces your ownership.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

N/A

—

Data not available

Profit after running costs

Operating Margin

N/A

—

Data not available

Return on the money invested

ROCE

-70.2%

Weak — -70.2% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

N/A

—

Data not available

Profit growth

EPS YoY

N/A

Data not available

How steady the profit is

EPS Consistency

4/8 quarters

Earnings inconsistent quarter-to-quarter

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

N/A

Data not available

Spare cash per sale

FCF Margin

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

N/A

Data not available

Covers its interest

Interest Cover

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

N/M

Negative earnings — P/E not meaningful

Cheaper or dearer next year

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial